vs
Side-by-side financial comparison of Plymouth Industrial REIT, Inc. (PLYM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $51.2M, roughly 1.1× Plymouth Industrial REIT, Inc.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -106.3%, a 23.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -1.4%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 0.4%).
Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PLYM vs RYTM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.2M | $57.3M |
| Net Profit | $-54.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -102.5% | -82.2% |
| Net Margin | -106.3% | -83.0% |
| Revenue YoY | -1.4% | 36.9% |
| Net Profit YoY | -248.5% | -9.6% |
| EPS (diluted) | $-1.23 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.3M | ||
| Q3 25 | $51.2M | $51.3M | ||
| Q2 25 | $47.2M | $48.5M | ||
| Q1 25 | $45.6M | $32.7M | ||
| Q4 24 | $47.6M | $41.8M | ||
| Q3 24 | $51.9M | $33.3M | ||
| Q2 24 | $48.7M | $29.1M | ||
| Q1 24 | $50.2M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-54.4M | $-52.9M | ||
| Q2 25 | $-6.1M | $-46.6M | ||
| Q1 25 | $5.8M | $-49.5M | ||
| Q4 24 | $147.4M | $-43.3M | ||
| Q3 24 | $-15.6M | $-43.6M | ||
| Q2 24 | $1.3M | $-32.3M | ||
| Q1 24 | $6.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | -102.5% | -102.6% | ||
| Q2 25 | -10.3% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | -29.6% | -132.0% | ||
| Q2 24 | 2.7% | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -106.3% | -103.1% | ||
| Q2 25 | -12.9% | -96.1% | ||
| Q1 25 | 12.8% | -151.4% | ||
| Q4 24 | 309.9% | -103.6% | ||
| Q3 24 | -30.1% | -131.2% | ||
| Q2 24 | 2.7% | -110.9% | ||
| Q1 24 | 12.4% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $-1.23 | $-0.82 | ||
| Q2 25 | $-0.14 | $-0.75 | ||
| Q1 25 | $0.13 | $-0.81 | ||
| Q4 24 | $3.24 | $-0.71 | ||
| Q3 24 | $-0.35 | $-0.73 | ||
| Q2 24 | $0.03 | $-0.55 | ||
| Q1 24 | $0.14 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $470.1M | $139.1M |
| Total Assets | $1.6B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M | ||
| Q1 24 | — | $201.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $646.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $139.1M | ||
| Q3 25 | $470.1M | $148.8M | ||
| Q2 25 | $539.6M | $-11.9M | ||
| Q1 25 | $571.0M | $18.9M | ||
| Q4 24 | $579.5M | $21.7M | ||
| Q3 24 | $436.5M | $11.2M | ||
| Q2 24 | $475.2M | $39.3M | ||
| Q1 24 | $484.6M | $61.6M |
| Q4 25 | — | $480.2M | ||
| Q3 25 | $1.6B | $506.9M | ||
| Q2 25 | $1.6B | $372.7M | ||
| Q1 25 | $1.4B | $386.7M | ||
| Q4 24 | $1.4B | $392.3M | ||
| Q3 24 | $1.5B | $363.6M | ||
| Q2 24 | $1.4B | $381.8M | ||
| Q1 24 | $1.4B | $258.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.12× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-25.4M | ||
| Q3 25 | $20.0M | $-26.6M | ||
| Q2 25 | $23.4M | $-23.3M | ||
| Q1 25 | $15.6M | $-40.4M | ||
| Q4 24 | $96.1M | $-18.8M | ||
| Q3 24 | $17.6M | $-25.2M | ||
| Q2 24 | $19.9M | $-29.1M | ||
| Q1 24 | $16.6M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.12× | — | ||
| Q1 24 | 2.67× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
